Supplementary Figures:

Supplementary Figure 1. Baseline values of single MBDA components in relapsing and non-relapsing RA patients

Baseline values of the 12 multi-biomarker disease activity (MBDA) components in RA patients experiencing a relapse or remaining in remission (no relapse). SAA, serum amyloid A; CRP, C-reactive protein; IL-6, interleukin 6; TNF-RI, tumour necrosis factor receptor 1; MMP-1, matrix metalloproteinase 1; MMP-3, matrix metalloproteinase 3; YKL-40, human cartilage glycoprotein 39 (YKL-40); EGF, epidermal growth factor; VEGF, vascular endothelial growth factor; EGF, epidermal growth factor; VEGF, vascular endothelial growth factor; VCAM1, vascular cell adhesion molecule-1.
Supplementary Figure 2. Relapse rates of RA dependent on clinical scores and rheumatoid factor

Kaplan-Meier curves indicate loss of remission over 12 months in patients with rheumatoid arthritis in relation to ACPA status and (A) C-reactive protein (CRP), (B) erythrocyte sedimentation rate (ESR), (C) disease activity 28 score (DAS28), (D) simplified disease activity index (SDAI), and (E) clinical disease activity index (CDAI). (blue) ACPA/respective parameter double- negative, (green) ACPA+/respective parameter-, (yellow) ACPA-/ respective parameter+ and (purple) ACPA/ respective parameter double positive. (F) Kaplan-Meier curve indicates loss of remission over 12 months in patients with rheumatoid arthritis in relation to rheumatoid factor (RF) status and multi-biomarker disease activity (MBDA) scores. (blue) RF/MBDA double- negative, (green) RF+/ MBDA-, (yellow) RF-/ MBDA+ and (purple) RF/MBDA double positive. Y-axis indicates the percentage of patients with rheumatoid arthritis in sustained remission (100% at baseline). X-axis indicates time.

Supplementary Figure 2